Document:

exhibit10203.htm

  

  

  

Exhibit 10.20.3

Portions of this exhibit were omitted and filed separately with the Secretary of the Securities and Exchange Commission pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.  Such portions are marked by [***].

AMENDMENT NO. 1 TO AMENDED AND RESTATED TASK ORDER NO. 1

This Amendment No. 1 to Amended and Restated Task Order No. 1 (this “Amendment”), effective as of February 1, 2010 (the “Effective Date”) is entered into between Pfizer Inc (“Pfizer”) and PDI, Inc. (“PDI”), pursuant to the Amended and Restated  Master Services Agreement, effective November 1, 2009 between Pfizer and PDI (as amended to the date hereof, the “Agreement”), and is subject to all the terms and conditions set forth therein, except as may be otherwise expressly provided herein.

In the event of a conflict between the terms of the Agreement thereto and the terms of this Amendment, the terms in this Amendment shall prevail.

This Amendment amends the Amended and Restated Task Order No. 1 to the Agreement entered into between Pfizer and PDI as of January 1, 2010 (the “Task Order No. 1”) as detailed below. There will be no additional costs to Pfizer as a result of these changes.  Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Task Order No. 1

Background & Purpose of this Amendment

The parties have a mutual desire to make certain changes to the Designated Physician list for the Program and wish to clarify that Designated Physicians who are at any time during an applicable quarter removed with Pfizer’s approval from the Designated Physician list will be excluded from the calculation of the achievement of PDI’s performance metrics pursuant to Task Order No. 1 for the applicable quarter.

In addition, in connection with PDI’s performance of its 2010 Key Performance Milestones as set forth in Section 2 of Task Order No. 1, [***].

Impact on Performance Metrics set forth in Task Order No. 1

The following revisions to the performance metrics set forth in Task Order No. 1 shall be effective as of the Effective Date: [***].

 

Turnover of PDI Personnel

 

 

The parties agree that all PDI personnel [***] pursuant to Section 13 of the Task Order No. 1.

 

	
  

	
***  Confidential material which has been omitted and filed separately with the Securities and Exchange Commission.

  

  

  

 

All other terms and conditions in the Task Order No. 1 that are not hereby amended are to remain in full force and effect.

 

	
PDI, INC.

	
PFIZER INC.

	  
	  
	
By: /s/ Nancy S. Lurker                                          

	
By: /s/ Chris Gish                                          

	
Name: Nancy S. Lurker                                          

	
Name: Chris Gish                                          

	
Title: Chief Executive Officer         

	
Title: Senior Director, Sales                          

                                              

 

  

2exhibit10204.htm

  

  

  

Exhibit 10.20.4

Portions of this exhibit were omitted and filed separately with the Secretary of the Securities and Exchange Commission pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.  Such portions are marked by [***].

AMENDMENT NO. 2 TO AMENDED AND RESTATED TASK ORDER NO. 1

This Amendment No. 2 to Amended and Restated Task Order No. 1 (this “Amendment No. 2”), effective as of June 28, 2010 (the “Effective Date”) is entered into by and between Pfizer Inc. (“Pfizer”) and PDI, Inc. (“PDI”), pursuant to the Amended and Restated Master Services Agreement by and between Pfizer and PDI entered into on September 23, 2009 (as amended to the date hereof, the “Agreement”), and is subject to all the terms and conditions set forth therein.

This Amendment amends the Amended and Restated Task Order No. 1 to the Agreement entered into by and between Pfizer and PDI as of January 1, 2010, as subsequently amended by that certain Amendment No. 1 to the Amended and Restated Task Order No. 1 effective as of February 1, 2010 (collectively, “Task Order No. 1”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in Task Order No. 1.

WHEREAS, the parties desire to define the conditions upon which PDI shall be entitled to earn the [***] available for 2010, and make certain other changes to Task Order No. 1;

NOW, THEREFORE, the parties hereby agree as follows:

	
  

	
1.

	
Section E of Task Order No. 1, entitled “Ongoing Program Management/Steady State”, is amended by deleting the following language from subsection 11 thereof appearing under the heading “[***].

	
  

	
2.

	
The following shall be substituted for the above-referenced deletion, it being intended that

the parties describe their agreement as to the methodology of PDI earning the [***].

PDI will have earned [***] with respect to each of the Products specified in the chart above for each of the First Period and the Second Period, respectively, if [***].

 

	
  

	
3.

	
Section B, entitled “Program Teams”, of Task Order No. 1 shall be amended by deleting the current PDI Contact Person and substituting the following therefor:

 

	
“PDI Contact Person:

	  	
Rick Shalaby

	  	  	
National Sales Director

	  	  	
PDI, Inc.

	  	  	
Morris Corporate Center, Building A

	  	  	
300 Interpace Parkway

	  	  	
Parsippany, NJ 07054

	  	  	
(862) 207-7800

	  	  	
rshalaby@pdi-inc.com”

	  	  	  

	
  

	
***  Confidential material which has been omitted and filed separately with the Securities and Exchange Commission.

  

  

  

 

4.           All other terms and conditions in Task Order No. 1 that are not hereby amended shall remain in full force and effect.  In the event of a conflict between the terms of this Amendment No. 2 and the terms of the Agreement or Task Order No. 1, the terms of this Amendment No. 2 shall prevail.

 

	
PDI, Inc.

	
PFIZER INC

	  
	  
	
By: /s/ Nancy S. Lurker                                           

	
By: /s/ Chris Gish                                           

	
Name: Nancy S. Lurker                                           

	
Name: Chris Gish                                           

	
Title: Chief Executive Officer

	
Title: Senior Director, Sales                                                      

 

  

2exhibit10205.htm

Exhibit 10.20.5

Portions of this exhibit were omitted and filed separately with the Secretary of the Securities and Exchange Commission pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.  Such portions are marked by [***].

AMENDMENT NO. 3 TO AMENDED AND RESTATED TASK ORDER NO. 1

This Amendment No. 3 to Amended and Restated Task Order No. 1 (this “Amendment No. 3”), effective as of October 1, 2010 (the “Effective Date”) is entered into by and between Pfizer Inc. (“Pfizer”) and PDI, Inc. (“PDI”), pursuant to the Amended and Restated Master Services Agreement by and between Pfizer and PDI entered into on September 23, 2009 (as amended to the date hereof, the “Agreement”), and is subject to all the terms and conditions set forth therein.

This Amendment No. 3 amends the Amended and Restated Task Order No. 1 (“Task Order No. 1”) entered into by and between Pfizer and PDI as of January 1, 2010, as subsequently amended by that certain Amendment No. 1 to the Amended and Restated Task Order No. 1 effective as of February 1, 2010, and as further amended by that certain Amendment No. 2 to the Amended and Restated Task Order No. 1 effective as of June 28, 2010.

Capitalized terms used but not defined in this Amendment No. 3 shall have the meanings ascribed to such terms in Task Order No. 1, as amended to date.

WHEREAS, the parties desire to waive certain call plan adherence goals and to confirm payment by Pfizer to PDI of certain [***] under Task Order No. 1 with respect to the third calendar quarter of 2010.

NOW, THEREFORE, the parties hereby agree as follows:

	
1.  

	
Notwithstanding anything to the contrary contained in Section 11 of Task Order No. 1 or elsewhere under Task Order No. 1 (as amended to date), Pfizer agrees to:  [***].

 

	
2.  

	
All other terms and conditions in Task Order No. 1 that are not hereby amended shall remain in full force and effect.  In the event of a conflict between the terms of this Amendment No. 3 and the terms of the Agreement or Task Order No. 1, the terms of this Amendment No. 3 shall prevail.

 

	
  

	
***  Confidential material which has been omitted and filed separately with the Securities and Exchange Commission.

  

  

  

IN WITNESS WHEREOF, the parties have caused this Amendment No. 3 to Amended and Restated Task Order No. 1 to be executed by their fully authorized representatives as of the date first above written.

	
PDI, INC.

	
PFIZER INC

	  
	  
	
By: /s/ Nancy S. Lurker                                          

	
By: /s/ Angela Hwang                                                     

	
Name: Nancy S. Lurker                                          

	
Name: Angela Hwang                                                     

	
Title: Chief Executive Officer         

	
Title: Vice President, U.S.                                          

	  	
           Established Brands                                          

 

  

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}]]